stockrowKrystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
- Revenue
- +30.2%
- EPS
- −22.3%
- Free cash flow
- +137.8%
Quarter to September 2026, against a year earlier
Follow KRYS
Alert me
Krystal Biotech, Inc. (KRYS) EPS (diluted)
Krystal Biotech, Inc.'s EPS (diluted) for fiscal 2025 was $6.84, up 128.0% from $3.00 in fiscal 2024. Over the twelve months to 30 September 2026 it was $7.37. Over the past ten years it has ranged from −$5.49 (fiscal 2022) to $6.84 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. Krystal Biotech, Inc. ranks 12th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $6.84 | 128.00% |
| FY2024 | $3.00 | 669.23% |
| FY2023 | $0.39 | — |
| FY2022 | −$5.49 | — |
| FY2021 | −$3.13 | — |
| FY2020 | −$1.71 | — |
| FY2019 | −$1.20 | — |
| FY2018 | −$0.97 | — |
| FY2017 | −$1.48 | — |
| FY2016 | −$1.31 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $2.05 | 14.25% |
| Jun 2026 | $1.79 | (2.19%) |
| Mar 2026 | $1.83 | 7.65% |
| Dec 2025 | $1.70 | (36.09%) |
| 36 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| KRYS Krystal Biotech, Inc. | $7.37 |
| TGTX TG Therapeutics, Inc. compare | $2.74 |
| PTGX Protagonist Therapeutics, Inc. compare | $1.03 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| IBRX ImmunityBio, Inc. compare | −$0.97 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| SYRE Spyre Therapeutics, Inc. compare | −$3.07 |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$5.98 |
| CYTK Cytokinetics, Incorporated compare | −$6.04 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on KRYS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement